Abstract
Neuroendocrine tumors are a heterogeneous group of neoplasms originating from endocrine cells, which are characterized by the presence of secretory granules as well as the ability to produce biogenic amines and polypeptide hormones. They are characterized by slow growth and frequent metastasis to the liver. The therapeutic approach to hepatic metastases should be considered with the number and distribution of the liver metastases. Liver transplantation should be considered in patients with neuroendocrine metastases to the liver that are not accessible with curative or cytoreductive surgery. We herein present a case with metastatic neuroendocrine tumor who underwent living donor liver transplantation and is surviving for 4 years.
Keywords:
Neuroendocrine tumor, liver transplantation, liver tumor
References
1
Yener O, Demiral G, Aksoy F, et al. Karsinoid tümöre bağlı gelişen intestinal iskemi: olgu sunumu. Ulusal Cerrahi Dergisi 2010; 26: 112–114.
2
Özlük Y, Güllüoğlu MG. Larinksin küçük hücreli nöroendokrin karsinomlarında TTF-1 ekspresyonu. Türk Patoloji Dergisi 2005; 21:17–20.
3
Yalçın K, Urakçı Z, Beştaş R, et al. Diffüz karaciğer metastazı ile başvuran bir hastada fonksiyonel olmayan nöroendokrin tümör: olgu sunumu. Akademik Gastroenteroloji Dergisi 2010; 9:27–31.
4
Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol 2007; 47:460–466. doi:10.1016/j.jhep.2007.07.004
5
Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15:966–973. doi:10.1093/annonc/mdh216
6
McLoughlin JM, Kuhn JA, Lamont JT. Neuroendocrine tumors of the pancreas. Curr Treat Opin Gastroenterol 2004; 7:355–364. doi:10.1007/s11938-004-0048-7
7
İnce AT, Tosun S. Gastroenteropankreatik nöroendokrin tümörler. Güncel Gastroenteroloji Dergisi 2005; 9:105–114.
8
Metz DC, Jensen RT. Endocrine tumors of the gastrointestinal tract and pancreas. In: Rustgi AK, ed. Gastrointestinal cancers. A companion to Sleisenger and Fordtrans. Gastrointestinal and Liver Disease. Edinburgh: Elsevier Science Ltd 2003; 681–719.
9
Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 1999;18:133–141.
10
Coppa J, Pulvirent A, Schiavio M, et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. Transpl Proc 2001; 33:1537–1539. doi:10.1016/S0041-1345(00)02586-0
11
Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995; 169:36–42. doi:10.1016/ S0002-9610(99)80107-X
12
Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, e-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002; 73:386–394. doi:10.1097/00007890-200202150-00012
13
Cahlin C, Friman S, Ahlman H, et al. Liver transplantation for metastatic neuroendocrine tumor disease. Transplant Proc 2003; 35:809–810. doi:10.1016/ S0041-1345(03)00079-4
14
Gregoire E, Le Treut YP. Liver transplantation for primary or secondary endocrine tumors. Transpl Int 2010; 23:704– 711. doi:10.1111/j.1432-2277.2010.01110.x
15
Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004; 8:208–212. doi:10.1016/j.gassur.2003.11.010
